Peter B. Corr, PhD
Peter B. Corr, PhD
Imvax Co-Founder and Chairman of the Board

Dr. Peter B. Corr is Co-Founder and Managing General Partner of Auven Therapeutics Management LLLP. Dr. Corr retired from Pfizer Inc in December 2006 where he was Senior Vice President for Science and Technology. He also headed worldwide pharmaceutical research and development for Pfizer. Previously, Dr. Corr served as Executive Vice President, Pfizer Global Research & Development, and President, Worldwide Development. He also served as Senior Vice President, Discovery Research, at Monsanto/Searle and then, President of Pharmaceutical Research and Development at Warner Lambert/Parke Davis.

Dr. Corr, who received his doctorate from Georgetown University School of Medicine, spent 18 years as a researcher in molecular biology and pharmacology at Washington University in St. Louis. When he left Washington University, Dr. Corr was Professor, Department of Medicine (Cardiology) and Professor, Department of Pharmacology and Molecular Biology. His research has been published in more than 160 scientific manuscripts.

Dr. Corr is the recipient of numerous awards, including membership in the Alpha Omega Alpha National Medical Honorary Society, an Established Investigator Award from the American Heart Association, and a Research Career Development Award from the National Institutes of Health. He received the Washington University Distinguished Faculty Award, as well as multiple Teacher of the Year awards.

He is a past Governor of the New York Academy of Sciences (and past Chairman of the Board of Governors) and past member of the Board of Regents of Georgetown University. Additionally, he is Immediate Past Chair of the Board of the International Partnership for Microbicides, Chairman of the Board of Directors for the Critical Path Institute (retired in June, 2016 after 10 years), and Chairman of the Board of Directors for ADC Therapeutics, S.A. through the completion of its IPO in May, 2020. He served as a founding Board member on the Board of Directors of Furiex Pharmaceuticals, Inc. until the sale of the company in July, 2014. He is Chairman Emeritus of the Board of Patient Assist VI from its founding which provides medicines to indigent patients in the US Virgin Islands. He is a member of the National Council for Washington University School of Medicine and the Barnes Hospital Medical Center.

Steven M. Altschuler, MD
Steven M. Altschuler, MD
Managing Director/Healthcare Ventures at Ziff Capital Partners

Steven Altschuler brings nearly 20 years of experience building and leading world-class, integrated, translational, value-based health care systems and transformational biotechnology companies. He currently serves as managing director of Healthcare Ventures at Ziff Capital Partners and was previously chair of the board of directors at Spark Therapeutics (now part of Roche) for six years, from its founding until it was acquired in 2019. In his role at Ziff Capital Partners, Dr. Altschuler co-leads the firm’s efforts towards investing in, and facilitating the startup and development of, companies with potentially transformative technologies that emphasize cellular and molecular approaches to human disease. He previously co-founded Spark Therapeutics to develop and commercialize the preclinical and clinical gene therapy programs advanced at the Children’s Hospital of Philadelphia (CHOP) and other institutions. He served as Spark’s board chair from its founding through its acquisition in 2019, which included leading the company through a successful transition to a public company and the launch of an approved commercial product, which was the first gene therapy for an inherited disease approved by the U.S. Food and Drug Administration and European Medicines Agency. Dr. Altschuler formerly held chief executive positions at CHOP and University of Miami Health System. He is a member of the board of directors of WW (formerly Weight Watchers International), Orchard Therapeutics, AsclepiX Therapeutics, ImVaX and Platelet Biogenesis. He is also an independent trustee of the Brigham and Women’s Physician Organization at Mass General Brigham. Dr. Altschuler holds a B.A. in mathematics and an M.D. from Case Western Reserve University.

David W. Andrews, MD
David W. Andrews, MD
Imvax Co-Founder, Chief Medical Officer

Anthony Alfred Chiurco, MD Professor of Neurological Surgery, Vice Chair of Clinical Services in the Department of Neurological Surgery, and Chief of the Division of Neuro-Oncology at Thomas Jefferson University Hospital.

As Chief Medical Officer at Imvax, Inc., Dr. Andrews communicates and engages with clinicians, researchers, and other key opinion leaders in the field regarding clinical development activities and potential product development. He develops strategic plans for the company’s product portfolio to ensure that development programs meet quality and safety standards required by patients, health care providers, and regulatory agencies. Dr. Andrews has a 30-year experience as an academic brain tumor neurosurgeon, completing residency at New York Presbyterian Cornell and a Fellowship at Memorial Sloan Kettering Cancer Center, both in New York, NY. As a junior attending neurosurgeon, he received a prestigious NIH Physician Scientist Award to study brain tumors and has devoted his career to find better treatment for glioblastoma. He currently resides at Thomas Jefferson University Hospital where he is Professor and Vice Chair of Clinical Services, Department of Neurological Surgery, and Chief of the Division of Neuro-Oncology.

Dr. Andrew’s raised nearly $7M dollars in philanthropy over a 20-year period to advance this promising immunotherapy platform for GBM, collaborating closely with his colleague Dr. Craig Hooper, a talented neuro-immunologist. He established the Brain Tumor Division at Thomas Jefferson University Hospital in 1995 and served as its Chief, expanding the Division to four neurosurgeons and two neuro-oncologists before stepping down to assume his role as a founder of Imvax, Inc. in 2015. Under his leadership, the Division became a national leader performing over 1,100 brain tumor treatments a year. His vision with Imvax, Inc. is to accelerate the development of this promising vaccine treatment.

David G. Bunning
David G. Bunning
Founder, Chief Executive Officer, and Chief Investment Officer of TLP Investment Partners LLC

Mr. Bunning is the Chief Executive Officer and Chief Investment Officer of the TLP Group, LLC (TLP), which he established in 2004. Investing in a broad range of asset classes in both public and private markets, TLP and its affiliates are the principal investing arm of the Bunning Family Office. Prior to TLP, Mr. Bunning joined Citadel Investment Group LLC (Citadel) in 1991 when the firm’s assets under management were less than $20 million. When Mr. Bunning left Citadel in 2004 as a Principal, Head of Global Credit Trading, and a member of the Management Committee the firm had assets under management in excess of $10 billion.

Mr. Bunning devoted a substantial amount of his time from 2004 through 2013 to supporting efforts to develop effective treatments for life-threatening food allergies, with the ultimate goal of developing a cure for this disease. In search for a cure, Mr. Bunning and his family foundation provided funding for research and built collaborative relationships among research leaders at universities across the country, including Harvard, Stanford, Northwestern, University of Chicago, Duke and Johns Hopkins. Mr. Bunning was instrumental in spearheading the inaugural Food Allergy Research & Education (FARE) symposium at Harvard Medical School. Bringing together thought leaders in food allergy research, the NIH, the Food and Drug Administration (FDA), the pharmaceutical industry, and patient advocates, these now annual symposiums aim to develop a coordinated strategy for the treatment of life-threatening food allergies.

Reinforced by his experiences with life-threatening food allergies, Mr. Bunning continues to believe in the positive impact that venture philanthropy and early stage biotechnology company incubation can have in achieving transformative healthcare outcomes.

Mr. Bunning has a B.A. from Harvard College and an MBA from the Booth School of Business at the University of Chicago. He is currently the Chairman of the board of directors for FARE, and has been an active member of the board of directors of Ann and Robert H. Lurie Children’s Hospital of Chicago, Ducks Unlimited, and the National Wrestling Coaches Association.

Ira Brind, JD
Ira Brind, JD
President, Brind Investments, Inc., Board of Trustees, Thomas Jefferson University Hospital, Trustee and former Chairman of the Board of Wistar Institute

 

Ira has extensive experience in private equity and venture capital investing, as well as running, acquiring and divesting companies, with primary experience in healthcare services, technology and biotechnology. Ira currently servesas a member of the Board of Trustees of The Wistar Institute (former Chair of the Board), the University of the Arts, The Connelly Foundation, Thomas Jefferson University, the Philadelphia Museum of Art, and Young Scholars Charter School.He is a former Partner in Pulse Equity Partners, a private equity firm specializing in healthcare and healthy living investments, and President of Brind Investments, Inc. where he focuses on investing in private equity, venture, real estate and hedge funds. Ira was also instrumental in the creation of the Jefferson-MyrnaBrindCenter for Integrative Medicine at Jefferson University Hospital, named a TopHospital in Integrative Medicine by Philadelphia Magazine. He is a past Chair of the Jefferson Health System and has served on the Boards of Directors of three public companies, and currently serves on several private Boards, including IMVAX. He received both a BA in Biology and a JD from the University of Pennsylvania, and an honorary Doctor of Fine Arts degree from the University of the Arts.

Wendy DiCicco
Wendy DiCicco
Executive and Board Advisor - Board Advantage, LLC

Wendy DiCicco is a veteran healthcare executive with 30 years of financial, operational and corporate development experience. Ms. DiCicco currently serves the emerging growth life sciences community in the role of board member or as financial, executive and board advisory consultant.  She currently serves as a consultant for several immuno-oncology and gene therapy companies, including often serving in the role of interim CFO.  Ms. DiCicco currently serves on the Boards of Directors of EyePoint Pharmaceuticals (NASDAQ: EYPT), where she serves as the Audit Committee Chair, Carmell Therapeutics, and ExpressCells, life sciences companies in the fields of ophthalmic pharmaceuticals, plasma-based regenerative medicine, and gene editing, respectfully.  

She was most recently the Chief Operating and Financial Officer of Centinel Spine, a privately-held designer, developer and worldwide distributor of spinal implants, where she established the Company’s international operations, and was instrumental in both the recapitalization of the Company and in corporate development and global commercialization initiatives.  She previously served as President and Chief Operating Officer of Camber Spine Technologies where she significantly expanded the Company’s operations, infrastructure and commercial organization. Prior to Camber Spine, she held several Chief Financial Officer roles at Nuron Biotech, Quench USA, Globus Medical and Kensey Nash Corporation. Her career started in public accounting at Deloitte & Touche.

Ms. DiCicco received a B.S. in accounting from Philadelphia College of Textiles and Science and is a licensed CPA. She is also an appointed Board Leadership Fellow and Corporate Governance Fellow of the National Association of Corporate Directors (NACD).

John P. Furey
John P. Furey
Imvax Chief Executive Officer

As Chief Executive Officer, John P. Furey leads the company’s development of its novel patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers. He also serves on the Imvax Board.

Most recently, John was Chief Operating Officer of Spark Therapeutics, Inc., where he led the successful US launch of LUXTURNA™, the first FDA-approved gene therapy for a genetic disease, and contributed to the build out of Spark as a fully integrated company. Prior to Spark, Mr. Furey served as Senior Vice President and Head of Global Operations at Baxalta, where he transformed the company’s global operations into a first-in-class supply chain network for rare diseases and led the 14,000-employee manufacturing, quality, engineering and process development organization. Earlier in his career, Mr. Furey initiated the restructuring and ultimate divestiture of Baxter International’s vaccines franchise to Pfizer. While at Pfizer, he transformed the China vaccine business into one of the company’s fastest growing units.

Mr. Furey also currently serves as non-executive director at Adaptimmune, a leader in T-cell therapy, and is an indepdent board member of Sensorion, a pioneering clinical-stage biopharmaceutical company developing therapies for the ear.

Mr. Furey earned an Executive MBA (Pharmaceutical Marketing) from St Joseph’s University, in Philadelphia, a Bachelor of Science with Honors from Trinity College, Dublin, and a Diploma in Environmental Health from the Dublin Institute of Technology.

Ted Koutouzis, MD
Ted Koutouzis, MD
Fixed Income Head of Healthcare Research, Fiscus Ventures and Reimagined Ventures (affiliates of Magnetar Capital)
Ted Koutouzis is a venture capitalist and medicine man. He is an analyst at Magnetar Capital, and the Managing Director at Reimagined Ventures.

Education
Koutouzis graduated from Florida State University with a BS in Nutrition/Exercise Science and an MD from the University of Miami School of Medicine. He received his graduate degree in Emergency medicine from Northwestern University.

Career
Koutouzis practices emergency medicine at Northwestern Memorial Hospital. In addition, Koutouzis has worked at Magnetar Capital since 2006. For the first ten years he focused on risk arbitrage investments at the equity desk and later moved on to the fixed income team where he was responsible for the underwriting process for structured finance solutions across the life sciences. He is the Managing Director at Reimagined Ventures where he co-manages all healthcare investments. He also sits on the board at Neural Analytics, a company that received a ten million dollar investment from Reimagined Ventures.

Thomas Pfisterer
Thomas Pfisterer
Head of Direct Investments, Wild Group Management AG

Thomas Pfisterer has served as a member of the board of directors of Imvax since 2019.

In addition to his position as member of the board of directors of Imvax, Inc., Thomas currently serves on the boards of directors of several other companies, including biotech companies ADC Therapeutics (NYSE:ADCT) (Epalinges, CH) and InSphero AG (Schlieren, CH), or pharma company Sermonix Pharmaceuticals Inc. (Columbus (OH), US).

Thomas Pfisterer also holds a senior management role at WILD Group Management AG heading the Direct Investments activities of the WILD Family Investment Office since the beginning of 2015.

He joined the Family Office following the sale of WILD Flavors GmbH, one of the world’s leading suppliers of natural ingredients to the food and beverage industry, for which he served as Head of Strategic Development directing the company’s global M&A activities since October 2011.

Previously, Mr. Pfisterer worked in the investment banking division of Morgan Stanley Bank AG in Frankfurt, focusing on M&A and capital market transactions for German healthcare clients.

Mr. Pfisterer holds a Master in Finance (MPhil) from Cambridge University, UK, as well as a Bachelor in Economics (B.A. HSG) and a Bachelor in Business Administration (B.A. HSG), both from University of St. Gallen, CH.

Peter B. Corr, PhD
Imvax Co-Founder and Board Chairman


John P. Furey
Imvax Chief Executive Officer


David W. Andrews, MD
Imvax Co-Founder, Interim Chief Executive Officer, Chief Medical Officer


Arthur W. Howe, IV, MBA
Imvax Co-Founder, Chief Financial Officer


Steven M. Altschuler, MD
Managing Director/Healthcare Ventures at Ziff Capital Partners and Chair, Board of Directors of Spark Therapeutics


Ira Brind, JD
President, Brind Investments, Inc., Board of Trustees, Thomas Jefferson University Hospital, Trustee and former Chairman of the Board of Wistar Institute.


Thomas Pfisterer
Head of Direct Investments, Wild Group Management AG


David G. Bunning
Founder, Chief Executive Officer, and Chief Investment Officer of The TLP Group LLC


Ted Koutouzis, MD
Fixed Income Head of Healthcare Research, Fiscus Ventures and Reimagined Ventures (affiliates of Magnetar Capital)


Nick Seaver
Managing Director/Investments at Ziff Capital Partners